Guilford (GLFD) - Steadily Rising Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Guilford (GLFD) - Steadily Rising

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tdinovo who wrote (121)	10/10/1997 4:20:00 PM
From: tdinovo	of 496

Sorry for delay. PJ report primarily goes over old information, but was generated as a result of an analysts meeting in NY on September 25. A few details are provided on dosing levels for the announced study and reference to two on-going, larger studies in monkeys. Both unreported studies are placebo-controlled; one to demonstrate neuroprotective effect of GPI-1046 and a second that is similar to (but larger than) the reported work. The latter study will include 60 and 90 day follow-up work and is supposed to be finished in Q4. The neuroprotective study is already complete and results are being analyzed. The authors speculate that Amgen will choose a lead product in Q1 1998 and will begin clinicals mid-year. They suggest GPI-1046 may be choice, which seems logical enough. Ted

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next